Skip to main content

Table 3 Patients characteristics by ROC cutoff points in PRAME gene expression

From: Correlation of preferentially expressed antigen of melanoma (PRAME) gene expression with clinical characteristics in acute leukemia patients

Characteristics

PRAME < 2.609 (n=27)

PRAME > 2.609 (n=15)

p value

Age (years)

35 (5–88)

41 (1–65)

0.4212

Gender: M/F

20/7 (74.07%/25.9%)

9/6 (60%/40%)

0.4880

WBC × 103/L

34.3 (12–100)

30.4 (3.7–99.9)

0.5038

Lymphocyte %

65.7 (1.6–99.9)

67.1 (1.7–99.9)

0.4155

Hb (g/dL)

9.8 (5.9–15.3)

10.4 (6.6–15)

0.4157

ESR (mm/h)

68 (15–140)

78.5 (39–140)

0.4345

Total protein (g/dL)

6.9 (4.8–8.3)

6.9 (5.4–8.2)

0.3262

Albumin (g/dL)

3.9 (2.5–4.5)

3.6 (2.7–4.8)

0.2626

Globulin (g/dL)

3.2 (2.3–4.8)

3.3 (2.4–4.2)

0.9818

A/G ratio

1.1(0.7–1.8)

1.16 (0.7–1.8)

0.6092

Bilirubin direct

0.4 (0–2.4)

0.6 (0–2.2)

0.6246

Bilirubin indirect

0.43 (0.05–3.1)

0.5 (0.1–1.4)

0.2755

Bilirubin total (mg/dL)

0.9 (0.1–3.7)

1.3 (0.2–3.7)

0.7170

SGOT (U/L)

31 (11–62)

43 (18–76)

0.2026

SGPT (U/L)

29 (6.4–118)

33 (11–72)

0.3988

ALP (U/L)

88 (55–170)

102 (56–212)

0.2185

Chloride (mg/dL)

98 (1.1–120)

107 (89–133)

0.0038**

Sodium (mg/dL)

136 (118–177)

137 (120–157)

0.3402

Potassium (mg/dL)

3.7 (2.8–6)

4.2 (3–6.3)

0.0358*

Blood urea (mg/dL)

24 (8–101)

33 (9–144)

0.3772

TLC × 109/L

23.1 (0.2–148)

33 (5.6–15)

0.7920

Creatinine

0.7 (0.2–1.7)

1.02 (0.2–2.3)

0.5621

Platelet count × 109/L

148 (2–800)

226 (10–825)

0.7229

ALC × 109/L

44.8 (1.7–97.7)

21.3 (9.1–74)

0.0216*

ANC × 109/L

57 (70–571)

170 (187–605)

0.6847

  1. Hb hemoglobulin, ESR erythrocyte sedimentation rate, SGOT Serum glutamic oxaloacetic transaminase, SGPT Serum glutamic pyruvic transaminase, ALP Alkaline phosphatases, TLC Total leucocyte count, ALC Absolute to lymphocyte ratio, NLR Neutrophil to lymphocyte ratio
  2. Highlighted values are indicating statistical significance at P < 0.05 (Where, P < 0.05*, P < 0.01**)